These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 19064725

  • 1. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A, Kraft M, Eliasson P, Labi V, Lam EW, Villunger A, Jönsson JI.
    Blood; 2009 Mar 05; 113(10):2302-11. PubMed ID: 19064725
    [Abstract] [Full Text] [Related]

  • 2. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.
    Acta Pharmacol Sin; 2015 Mar 05; 36(3):385-99. PubMed ID: 25640477
    [Abstract] [Full Text] [Related]

  • 3. PUMA and BIM are required for oncogene inactivation-induced apoptosis.
    Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH.
    Sci Signal; 2013 Mar 26; 6(268):ra20. PubMed ID: 23532334
    [Abstract] [Full Text] [Related]

  • 4. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
    Scheijen B, Ngo HT, Kang H, Griffin JD.
    Oncogene; 2004 Apr 22; 23(19):3338-49. PubMed ID: 14981546
    [Abstract] [Full Text] [Related]

  • 5. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X, Liu L, Sternberg D, Tang L, Galinsky I, DeAngelo D, Stone R.
    Cancer Res; 2005 Aug 15; 65(16):7338-47. PubMed ID: 16103085
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y.
    Clin Cancer Res; 2019 Nov 15; 25(22):6815-6826. PubMed ID: 31320594
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, Thiede C.
    Ann Hematol; 2010 Jul 15; 89(7):653-62. PubMed ID: 20119833
    [Abstract] [Full Text] [Related]

  • 8. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
    Yamawaki K, Shiina I, Murata T, Tateyama S, Maekawa Y, Niwa M, Shimonaka M, Okamoto K, Suzuki T, Nishida T, Abe R, Obata Y.
    Sci Rep; 2021 Nov 22; 11(1):22678. PubMed ID: 34811450
    [Abstract] [Full Text] [Related]

  • 9. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
    Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI.
    Br J Haematol; 2011 Oct 22; 155(2):198-208. PubMed ID: 21848891
    [Abstract] [Full Text] [Related]

  • 10. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
    Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K.
    Blood; 2009 Dec 03; 114(24):5034-43. PubMed ID: 19808698
    [Abstract] [Full Text] [Related]

  • 11. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR.
    Clin Cancer Res; 2018 Jan 01; 24(1):234-247. PubMed ID: 29074603
    [Abstract] [Full Text] [Related]

  • 12. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
    Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, Marmsater F, Robinson JE, Gross SD, Martinson M, Allen S, Kallan NC, Levis M.
    Leuk Res; 2012 Feb 01; 36(2):224-31. PubMed ID: 21802138
    [Abstract] [Full Text] [Related]

  • 13. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.
    Zhang W, Konopleva M, Burks JK, Dywer KC, Schober WD, Yang JY, McQueen TJ, Hung MC, Andreeff M.
    Cancer Res; 2010 Mar 15; 70(6):2424-34. PubMed ID: 20215498
    [Abstract] [Full Text] [Related]

  • 14. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
    Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.
    J Biol Chem; 2003 Aug 29; 278(35):32892-8. PubMed ID: 12815052
    [Abstract] [Full Text] [Related]

  • 15. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
    Ahmad R, Liu S, Weisberg E, Nelson E, Galinsky I, Meyer C, Kufe D, Kharbanda S, Stone R.
    Mol Cancer Res; 2010 Jul 29; 8(7):986-93. PubMed ID: 20571062
    [Abstract] [Full Text] [Related]

  • 16. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z, Du J, Hui H, Kan S, Huo T, Zhao K, Wu T, Guo Q, Lu N.
    Theranostics; 2021 Jul 29; 11(1):93-106. PubMed ID: 33391463
    [Abstract] [Full Text] [Related]

  • 17. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G, Caligiuri MA.
    Leukemia; 2015 Dec 29; 29(12):2382-9. PubMed ID: 26172401
    [Abstract] [Full Text] [Related]

  • 18. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS.
    Clin Cancer Res; 2012 May 01; 18(9):2502-14. PubMed ID: 22351686
    [Abstract] [Full Text] [Related]

  • 19. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT, Levis M, Small D.
    Br J Haematol; 2006 Sep 01; 134(5):500-9. PubMed ID: 16869825
    [Abstract] [Full Text] [Related]

  • 20. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K, Bolck HA, Buchwald M, Spielberg S, Polzer H, Spiekermann K, Bug G, Heinzel T, Böhmer FD, Krämer OH.
    Mol Cancer Ther; 2012 Nov 01; 11(11):2373-83. PubMed ID: 22942377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.